摘要
目的:探究与观察阿芬太尼联合七氟烷对扁桃体摘除术患儿血流动力学、凝血及疼痛介质表达的影响。方法:选取2019年1月-2020年3月本院80例扁桃体摘除术患儿,按照随机数字表法将其分为对照组和观察组,每组40例。对照组采用丙泊酚联合阿芬太尼麻醉,观察组采用阿芬太尼联合七氟烷麻醉。比较两组血流动力学指标(HR、MAP)、凝血指标(APTT、TT、PT)及疼痛介质(血清PGE_(2)、SP、5-HT)。结果:麻醉前,两组HR、MAP、APTT、TT、PT比较,差异均无统计学意义(P>0.05);麻醉后5 min及拔管后5 min,观察组HR、MAP、APTT、TT、PT均低于对照组,差异均有统计学意义(P<0.05)。麻醉前,两组PGE_(2)、SP、5-HT比较,差异均无统计学意义(P>0.05);术后2、4、6 h,观察组PGE_(2)、SP、5-HT均低于对照组,差异均有统计学意义(P<0.05)。结论:阿芬太尼联合七氟烷对扁桃体摘除术患儿血流动力学、凝血及疼痛介质表达的影响相对更为积极,应用价值相对更高。
Objective:To investigate and observe the influence of Alfentanil combined with Sevoflurane for hemodynamics,coagulation and pain mediators of children with tonsillectomy.Method:A total of 80 children with tonsillectomy in our hospital from January 2019 to March 2020 were selected,and they were divided into control group and observation group according to random number table method,40 cases in each group.The control group was treated with Propofol combined with Alfentanil,and the observation group was treated with Alfentanil combined with Sevoflurane.Hemodynamic indexes(HR,MAP),coagulation indexes(APTT,TT,PT)and pain mediators(serum PGE_(2),SP and 5-HT)were compared between two groups.Result:Before anesthesia,there were no significant differences in HR,MAP,APTT,TT and PT between two groups(P>0.05);5 min after anesthesia and 5 min after extubation,HR,MAP,APTT,TT and PT in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Before anesthesia,there were no significant differences in PGE_(2),SP and 5-HT between two groups(P>0.05);2,4 and 6 h after surgery,PGE_(2),SP and 5-HT in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:The effects of Alfentanil combined with Sevoflurane on hemodynamics,coagulation and expression of pain mediators in children with tonsillectomy are relatively more positive,and the application value is relatively higher.
作者
殷卓
于生喜
刘明
YIN Zhuo;YU Shengxi;LIU Ming(Dalian Women and Children’s Medical Group,Dalian 116000,China;不详)
出处
《中国医学创新》
CAS
2021年第29期170-173,共4页
Medical Innovation of China
